Opinion|Videos|November 30, 2023
Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma
Beyond symptoms, doctors consider the psychosocial factors impacting treatment access and adherence, like insurance coverage, cost, family support, and preexisting conditions, when deciding between immunotherapy and targeted therapy for patients with BRAF-mutated metastatic melanoma.
Advertisement
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5